Obstetrics & Gynecology Doctors in Weslaco, TX Accepting Medicare

8 Obstetrics & Gynecology doctors found. Showing 1 - 8

Dr. Mona H Mallikarjuniah, MD. Obstetrics & Gynecology - Obstetrics Medicare: Accepting Medicare Assignments Practice Location: 1604 E 8th St Ste B, Weslaco, TX 78596 Phone: 419-377-4320    Fax: 956-973-9916

Rory N Minck, MD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 1600 E Us Highway 83, Ste C, Weslaco, TX 78596 Phone: 956-969-8903    Fax: 956-969-8903

Dr. Juan J Gonzalez-dickson, MD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 909 James St, Suite A, Weslaco, TX 78596 Phone: 956-968-0802    Fax: 956-969-3242

Dr. Gregoris Elias Nunez, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1604 E 8th St, Suite B, Weslaco, TX 78596 Phone: 956-973-9717    Fax: 956-973-9916

Mrs. Elizabeth Gopal Krishnan, MD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 1331 E 6th St, Weslaco, TX 78596 Phone: 956-968-9502    Fax: 956-968-7269

Crystal Caballero, MSN, FNP-BC Obstetrics & Gynecology - Obstetrics Medicare: Not Enrolled in Medicare Practice Location: 913 S Airport Dr Ste A, Weslaco, TX 78596 Phone: 956-647-5529    Fax: 956-647-5617

Dr. Gabriela Abigail Villanueva, M.D., M.P.H. Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 913 S Airport Dr, Weslaco, TX 78596 Phone: 956-647-5529

Annabelle Lopez, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 913 S Airport Dr Ste A, Weslaco, TX 78596 Phone: 956-647-5529    Fax: 956-647-5617

News Archive

Ampio Pharmaceuticals receives FDA IND approval to start clinical trial of Ampion

Ampio Pharmaceuticals, Inc. today announced FDA acceptance of its IND and the treatment of the first fifteen (15) patients in its clinical trial using Ampion™ to treat osteoarthritis of the knee.

Bayer announces new data on novel anti-cancer compound

Bayer today announced results from Phase I and II trials of BAY 73-4506, a potent oral multi-kinase inhibitor currently being studied in multiple tumor types. These data were presented at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO).

Spectrum Pharmaceuticals initiates enrollment in Phase 2b ozarelix study for prostate cancer

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced initiation of patient enrollment in the second part of the Company's randomized Phase 2 clinical program of ozarelix, a luteinizing hormone-releasing hormone (LHRH) antagonist, in men with prostate cancer for whom hormonal treatment is indicated.

Democratic leaders still pondering reconciliation pros and cons for health bill

Congressional Democrats are facing a critical decision about whether to use the procedural maneuver known as budget reconciliation to pass a health care reform bill, The New York Times reports.

Read more Medical News

› Verified 4 days ago